References
Conn J.W. The evolution of primary aldosteronism: 1954–1967, Harvey Lectures, 62: 257, 1968.
Conn J.W., Cohen E.L., Rovner D.R. Suppression of plasma renin activity in primary aldosteronism: distinguishing primary from secondary aldosteronism in hypertensive disease. J. Am. Med. Ass. 190: 213, 1964.
Conn J.W., Cohen E.L., Rovner D.R., Nesbit R.M. Normokalaemic primary aldosteronism, a detectable cause of curable “essential” hypertension. J. Am. Med. Ass. 193: 200, 1965.
Kaplan N.M. Commentary on incidence of primary aldosteronism. Current estimations based on objective data. Arc. Intern. Med. 123: 152, 1969.
Fishman L.M., Kuchal O., Liddle G.W., Michelakis A.M., Gordon R.D., Chick W.T. “Incidence of primary aldosteronism in uncomplicated “essential” hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria”. J. Am. Med. Ass. 205: 497, 1968.
Ganguly A., Dowdy A.J., Luctscher J.A., Melada G.A. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma. J. Clin. Endocrinol. Metab. 36: 401, 1973.
Wisgerhof M., Brown R.D., Hogan M.J., Carpenter P.C., Edis A.J. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. J. Clin. Endocrinol. Metab. 52: 195, 1981.
Ganguly A., Melada G.A., Luctscher J.A., Dowdy A.J. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J. Clin. Endocrinol. Metab. 37: 765, 1973.
Gordon R.D., Hamlet S.M., Tunny T.J., Klemm S.A. Aldosterone-producing adenomas responsive to angiotensin pose problems in diagnosis. Clin. Exp. Pharmacol. Physiol. 14: 175, 1982.
Gordon R.D., Gomez-Sanchez C.E., Hamlet S.M., Tunny T.J., Klemm S.A. Angiotensin-responsive aldosterone-producing adenomas masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J. Hypertension. 5(Suppl 5): S103, 1987.
Tunny T.J., Gordon R.D., Klemm S.A., Cohn D. Histological as well as biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin. Clin. Endocrinol. 34: 363, 1991.
Gordon R.D., Stowasser M., Tunny T.J., Klemm S.A., Finn W.L., Krek A.L. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin. & Exper. Pharm. & Physiol. 18: 283, 1991.
Gordon R.D., Stowasser M., Klemm S.A., Tunny T.J. Primary aldosteronism and other forms of mineralocorticoid hypertension. In: Textbook of Hypertension. Ed. Swales J.D. Blackwell. Scientific. 865, 1995.
Gordon R.D., Klemm S.A., Tunny T.J., Stowasser M. Primary aldosteronism: hypertension with a genetic basis. Lancet 340: 159, 1992.
Gordon R.D., Stowasser M., Klemm S.A., Tumly T.J. Primary aldosteronism — some genetic, morphological, and biochemical aspects of subtypes. Steroids 60: 35, 1995.
Gordon R.D. Mineralocorticoid hypertension. Lancet. 344: 240, 1994.
Iida A., Blake K., Tunny T., Klemm S., Stowasser M., Hayward N., Gordon R., Nakamura Y., Imai T. Allelic losses on chromosome band 11q 13 in aldosterone producing adrenal tumors. Genes., Chromosomes. & Cancer. 12: 73, 1995.
Clarke D., Wilkinson R., Johnston I.D.A., Hacking P.M., Haggith P.M. Severe hypertension in primary aldosteronism and good response to surgery. Lancet 1: 482, 1979.
Murphy B.F., Whitworth JA, Kincaid-Smith P. Malignant hypertension due to an aldosterone-producing adrenal adenoma. Clin. Exp. Hypertens. Theory. Pract. A 7: 939, 1985.
Robertson P.W., Klidjian A., Harding L.K., Walters G., Lee M.R., Robb-Smith A.H.T. Hypertension due to a renin-secreting tumour. Am. J. Med. 43: 963, 1967.
Corvol P., Pinet F., Galen F.X., Plovin P.F., Chatellier G., Pagney J.Y., Bruneval P., Camilleri J.P., Menard J. Primary reninism. In Laragh J.H., Brenner B.M. (Eds), Hypertension: Pathophysiology, Diagnosis and Management, p. 1573 Raven Press, New York. 1995.
Gordon R.D., Klemm S.A., Tunny T.J., Stowasser M. Genetics of primary aldosteronism. Clin. & Exper. Pharm. & Physiol. 21: 915, 1994.
Davies C.J., Joplin G.F., Wclbourn R.B. Surgical management of the ectopic ACTH syndrome. Ann.Surg. 196: 46, 1982.
Jex R.K., van Heerden J.A., Carpenter P.C., Grant C.S. Ectopic ACTH syndrome. Diagnostic and therapeutic aspects. Am. J. Surg. 149: 276, 1985.
Findling J.W., Tyrrell J.B. Occult ectopic secretion of corticotropine. Arch. Intern. Med. 146: 929, 1986.
Biglieri E.C. Spectrum of mineralocorticoid hypertension. Hypertension 18: 251, 1991.
Molhuysen J.A., Gerbrandy J., de Vries L.A., De Jong J.C., Lenstra J.B., Turner K.P., Borst J.G.G. A licorice extract with desoxycortone-like action. Lancet. ii: 381, 1950.
Conn J.W., Rovner D.R., Cohen E.L. Licorice-induced pseudoaldosteronism. J. Am. Med. Ass. 205: 492, 1968.
Cumming A.M.M., Boddy K., Brown J.J., Fraser R., Lever A.F., Padfield P.L., Robertson J.I.S. Severe hypokalaemia with paralysis induced by small doses of licorice. Postgrad. Med. J. 56: 526, 1980.
Ulick S., Levine L.S., Gunezler P., Zanconato G., Ramirez L.C., Raugh W. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J. Clin. Endocrinol. Metab. 49: 757, 1979.
Stewart P.M., Corrie J.E.T., Shackleton C.H.L., Edwards C.R.W. Syndrome of apparent mineralocorticoid excess: a defect in the cortisol — cortisone shuttle. J. Clin. Invest. 82: 349, 1988.
Shackleton C.H.L., Stewart P.M. The hypertension of apparent mineralocorticoid excess (AME) syndrome. In: Biglieri EG, Melby JC. eds. Endocrine hypertension. Raven. Press; p 153, 1990.
Shimkets R.A., Warnoch D.G., Bositis C.M., Nelson-Williams C., Hansson J.H., Schambelan M., Gill J.R., Ulick S., Milora R.V., Findling J.W., Canessa C.M., Rossier B.C., Lifton R.P. Liddle’s syndrome: Heritable human hypertension caused by mutations in the β subunit of the epitheliai sodium channel. Cell. 79: 409, 1994.
Gordon R.D., Klemm S.A., Tunny T.J. Renin in Liddle’s syndrome and in the syndrome of apparent mineralocorticoid excess. In: Robertson J.I.S., Nicholls M.G. (eds) The Renin-Angiotensin System. London, Gower Medical Publishing, 1993.
Hiramatsu K., Yamada T., Yukimura Y., Komiya I, Ichikawa K., Ishihara M. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch. Intern. Med. 141: 1589, 1981.
Anonymous. The early diagnosis of primary aldosteronism. JAMA 201: 20, 1967.
Hamlet S.M., Tunny T.J., Woodland E., Gordon R.D. Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin. Exp. Pharmacol. Physiol. 12: 249, 1985.
Lins P.-E., Adamson U. Plasma aldosterone-plasma renin activity ratio. A simple test to identify patients with primary aldosteronism. Acta. Endocrinologica 113: 564, 1986.
Gordon R.D., Ziesak M.D., Tunny T.J., Stowasser M., Klemm S.A. Evidence that primary aldosteronism may not be uncommon — twelve percent incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol. 20: 296, 1993.
Gordon R.D., Klemm S.A., Tunny T.J., Stowasser M. Gordon’s Syndrome: A sodium-volume-dependent form of hypertension with a genetic basis. In: Hypertension: Pathophysiology, diagnosis and management. 2nd ed. Laragh JH & Brenner BM (eds.) 1995; Raven Press, New York.
Nadler J.L., Horton R, Hsueh W. Therapeutic effect of calcium blockade in primary aldosteronism (Abstract). Clin. Res. 32: 21A, 1984.
Iimura O., Kikuchi K., Shimamoto K., Nozawa A., Hasegawa R., Homma C. Effects of nisoldipine on sympathetic activity, the renin-angiotensin-aldosterone system, and watersodium-calcium metabolism in patients with essential hypertension. Arzheim-Forsch/DrugRes. 39: 710, 1989.
Staessen J., Lijnen P., Fagard R., Hespel P., Tan W.P., Devos P., Amery A. Effect of the calcium entry blocker isradipine (PN 200-110) in essential hypertension. J. Cardiovasc. Pharmacol. 13: 271, 1989.
Luft F.C., Aronoff G.R., Sloan R.S., Fineberg N.S., Weinberger M.H. Calcium channel blockade with nitrendipine: effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans. Hypertension 7: 438, 1985.
McKenna T.J., Sequeira S.J., Heffeman A., Chambers J., Culmingham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism. J. Clin. Endocrinol. Metab. 73: 952, 1991.
Collins R.D., Weinberger M.H., Dowdy A.J., Nokes G.W., Gonzales C.M., Leutscher J.A. Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension; relation to plasma renin activity. J. Clin. Invest. 49: 1415, 1970.
Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Gook S., Ulick S., Lalouel J.M. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355: 262, 1992.
Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Gutkin M., Fallo F., Gill J.R. Jr. Feld L., Ganguly A., Laidlaw J.C., Murnagham D.J., Kaufman C., Stockigt J.R., Ulick S., Lalouel J.M. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nature Genetics. 2: 66, 1992.
Jonsson J.R., Klemm S.A., Tunny T.J., Stowasser M., Gordon R.D. A new genetic test for familial hyperaldosteronism tye I aids in the detection of curable hypertension. Biochem. & Biophy. Res. Comm. 207: 565, 1995.
Soma R., Miyamori I., Nakagawa A., Matsubara T., Takasaky H., Morise T., Koni I., Takeda R., Kobayashi T. Possible association of aldosterone producing adenoma and non-fuctioning adrenal tumour. J. Endocrinol. Invest. 12: 183, 1989.
Vaughan N.J.A., Jowett T.P., Slater J.D.H., Wiggins R.C., Lightman S.L., Ma J.T.C., Payne N.N. The diagnosis of primary aldosteronism. Lancet i: 120, 1981.
Rutherford J.C., Stowasser M., Klemm S.A., Tunny T.J., Gordon R.D. Laparoscopic adrenalectomy for adrenal tumours causing hypertension and for “incidentalomas” of the adrenal on CT scanning. Clin. Exper. Pharmacol. Physiol. 1995 (in press).
Ross N.S., Aron D.C. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. New Engl. J. Med. 323: 1401, 1990.
Francis I.R., Gross M.D., Shapiro B., Korobkin M., Quint L.E. Integrated imagery of adrenal disease. Radiology 184: 1, 1992.
Osella G., Terzolo M., Borretta G., Magro G., Ali A., Piovesan A., Paccotti P., Angeli A. Endocrine evaluation of the incidentally discovered adrenal masses (Incidentalomas). J. Clin. Endocrinol. Metab. 79: 1532, 1994.
Herrara M.F., Grant C.S., van Heerden J.A., Sheedy P.E., Ilstrup D.M. Incidentally discovered adrenal tumours: an institutional perspective. Surgery 110: 1014, 1991.
Hamwi G.J., Serbin R.A., Kruger F.A. Does adrenocortical hyperplasia result in adrenocortical carcinoma? N. Engl. J. Med. 257: 1153, 1957.
Sutherland D.J.A., Ruse J.L., Laidlaw J.C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can. Med. Assoc. J. 95: 1109, 1966.
Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16: 363, 1954.
Skogseid B., Larsson C., Lindgren P-G., Kvanta E., Rastad J., Theodorsson E., Wide L., Wilander E., Oberg K. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type I. J. Clin. Endocrinol. Metab. 75: 76, 1992.
Beckers A., Abs R., Willems P.J., van der Auwea B., Kovacs K., Reznik M., Stevenaert A. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type I (MEN-I): Loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN-I locus. J. Clin. Endocrinol. Metab. 75: 564, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gordon, R.D. Primary aldosteronism. J Endocrinol Invest 18, 495–511 (1995). https://doi.org/10.1007/BF03349761
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349761